Boyle Scott N
SEC CIK 1913897 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| CCCC | C4 Therapeutics, Inc. | Chief Business Off | 306.1K | — | $3,651 | 19 | 2022-05-25 | 2026-02-13 |
Most active insiders at CCCC, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | REYNO LEONARD | Chief Medical Off | — | $22.2K |
| 2 | Mahaney Paige | CSO | — | — |
| 3 | Mossler Mark | CAO | — | — |
| 4 | Adams Kendra | CFO | — | — |
| 5 | Boyle Scott N | Chief Business Off | — | — |
| 6 | Anderson Kenneth Carl | Dir | — | — |
| 7 | Schick Kelly | CHRO | — | — |
| 8 | GROGAN DONNA ROY | Dir | — | — |
| 9 | Hirsch Andrew | Pres, CEO, Dir | — | — |
Transactions 19
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-02-18 | 2026-02-13+ | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | F - Tax | $1.89 | -9,004 | 306.1K | -3% | -$17.0K |
| M | 2026-02-18 | 2026-02-13+ | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | M - OptEx | $0.00 | +25.9K | 307.8K | +9% | $0 |
| 2026-02-18 | 2026-02-13 | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | A - Grant | $0.00 | +200.0K | 307.8K | +186% | $0 | |
| D | 2025-02-18 | 2025-02-14 | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | A - Grant | $0.00 | +56.5K | 111.3K | +103% | $0 |
| DM | 2025-02-18 | 2025-02-13+ | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | F - Tax | $3.19 | -4,103 | 108.5K | -4% | -$13.1K |
| DM | 2025-02-18 | 2025-02-14+ | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | S - Sale | $3.15 | -1,159 | 107.8K | -1% | -$3,651 |
| D | 2024-11-12 | 2024-11-07 | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | F - Tax | $6.04 | -1,102 | 56.6K | -2% | -$6,656 |
| D | 2024-11-12 | 2024-11-07 | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | M - OptEx | — | +3,750 | 57.7K | +7% | — |
| D | 2024-09-17 | 2024-09-16 | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | F - Tax | $6.36 | -661 | 53.9K | -1% | -$4,204 |
| D | 2024-09-17 | 2024-09-16 | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | M - OptEx | — | +2,250 | 54.6K | +4% | — |
| D | 2024-02-15 | 2024-02-14 | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | A - Grant | $0.00 | +27.3K | 52.3K | +109% | $0 |
| D | 2024-02-15 | 2024-02-13 | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | F - Tax | $6.53 | -1,735 | 25.0K | -6% | -$11.3K |
| D | 2023-08-31 | 2023-08-30 | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | F - Tax | $2.93 | -661 | 26.8K | -2% | -$1,937 |
| D | 2023-08-31 | 2023-08-30 | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | M - OptEx | — | +2,250 | 27.4K | +9% | — |
| D | 2023-02-15 | 2023-02-13 | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | A - Grant | $0.00 | +20.0K | 25.2K | +386% | $0 |
| D | 2023-02-01 | 2023-01-30 | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | F - Tax | $7.78 | -1,222 | 5,176 | -19% | -$9,507 |
| D | 2023-02-01 | 2023-01-30 | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | M - OptEx | — | +3,750 | 6,398 | +142% | — |
| A | 2022-06-14 | 2022-05-26 | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | F - Tax | $7.01 | -1,102 | 2,648 | -29% | -$7,725 |
| D | 2022-05-27 | 2022-05-25 | CCCC | C4 Therapeutics, Inc. | Boyle Scott N | Chief Business Off | M - OptEx | — | +3,750 | 3,750 | New | — |
Purchase Sale Sale after option exercise All abbreviations